Graham Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Graham Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,426	Closed	-$436K	–	1193
2025 Q3	$436K	Buy	20,426 +3,371	+20%	+$79.7K	0.01%	669
2025 Q2	$368K	Sell	17,055 -81,631	-83%	-$1.52M	0.01%	925
2025 Q1	$1.64M	Buy	98,686 +36,909	+60%	+$671K	0.03%	398
2024 Q4	$1.13M	Buy	+61,777	New	+$997K	0.02%	456
2024 Q2	–	Sell	-23,238	Closed	-$430K	–	1006
2024 Q1	$430K	Buy	23,238 +13,908	+149%	+$345K	0.01%	669
2023 Q4	$292K	Buy	+9,330	New	+$223K	0.01%	738
2022 Q2	–	Sell	-17,374	Closed	-$420K	–	974
2022 Q1	$420K	Buy	+17,374	New	+$420K	0.01%	616

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Graham Capital Management's ACAD Position: Q4 2025 in Review

Graham Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 20,426 shares — an estimated $436K sold.

Graham Capital Management first reported a position in ACAD in Q1 2022 and held it in 7 quarters. The position peaked at $1.64M in Q1 2025. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Graham Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Graham Capital Management sold 20,426 Acadia Pharmaceuticals shares in Q4 2025, an estimated $436K.
Graham Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Graham Capital Management's Acadia Pharmaceuticals position peaked at $1.64M in Q1 2025.
336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.